FFO
OTLK icon

Fortitude Family Office’s Outlook Therapeutics OTLK Stock Holding History

Fortitude Family Office’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.27K Sell
1,429
-1,125
-44% -$698 ﹤0.01% 1437
2026
Q1 		$526 Buy
2,554
+2,130
+502% +$920 ﹤0.01% 1709
2025
Q4 		$670 Buy
+424
New +$677 ﹤0.01% 1606

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Fortitude Family Office's OTLK Position: Q2 2026 in Review

Fortitude Family Office reduced its Outlook Therapeutics (OTLK) stake by 44% in Q2 2026, selling an estimated $698 and leaving 1,429 shares worth $2.27K. The position accounts for ﹤0.01% of the portfolio, ranked #1437.

Fortitude Family Office first reported a position in OTLK in Q4 2025 and has held it in 3 quarters since. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Fortitude Family Office held 1,429 shares of Outlook Therapeutics worth $2.27K as of Q2 2026.
  • Fortitude Family Office sold 1,125 Outlook Therapeutics shares in Q2 2026, an estimated $698.
  • Outlook Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1437 holding.
  • Fortitude Family Office first reported a position in Outlook Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.